



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/519,093

04/11/2005

Udi Damari

26479U

6784

20529

7590

08/13/2008

NATH & ASSOCIATES
112 South West Street
Alexandria, VA 22314

EXAMINER

SKOWRONEK, KARLHEINZ R

ART UNIT

PAPER NUMBER

1631

MAIL DATE

DELIVERY MODE

08/13/2008

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

DETAILED ACTION

Claim Status

Claims 75-90 are pending.

Claims 1-74 are cancelled.

Claims 89-90 are withdrawn as being directed to a non-elected invention.

Claims 75-88 have been examined.

Specification

Response to Arguments

Applicant's arguments, see remarks p 6, filed 15 May 2008, with respect to the objection to the specification as containing hyperlinks and trademarks have been fully considered. The objection to the specification has been withdrawn in view of the amendments to the specification to correct formalities.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.

Art Unit: 1631

2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claim 75-88 is rejected under 35 U.S.C. 103(a) as being unpatentable over Gianaroli et al. (Human Reproduction, Vol. 15 No. 10, p 2241-2246, 2000), in view of Whisler et al. (Clinical Chemistry, Vol. 36, No9, p. 1587-1588, 1990).

The claims are directed to a method of controlling the processing of components involved in an *in vitro* fertilization (IVF) in which a matching set of two or more components are defined; each of the components is assigned a unique machine-readable identification mark; providing on each component the identification mark; reading the identification mark of a component to verify that the component belongs to the matching set. In some embodiments, the components that are marked are consists of holders, physician, embryos,

Art Unit: 1631

oocytes, spermatozoa. In some embodiments, the matching set includes an embryo and a recipient. In some embodiments, the identification mark assigned to components is different. In some embodiments, the matching set includes a sperm and an oocyte. In some embodiments, a matching set corresponds to a biological entity and a holder. In some embodiments, an entity is within a holder and the holder is labeled. In some embodiments, the identification marks assigned to the components are the same. In some embodiments, the patient and their records are matched through the assignment of an identification mark. In some embodiments, the barcode is readable by scanning. In some embodiments, the identification mark is a barcode. In some embodiments, the identification mark is an image readable mark. In some embodiments, a label having the identification mark is affixed to a holder.

Gianaroli et al. shows a method for controlling the processing of components used in *in vitro* fertilization. Gianaroli et al. shows that a matching set of two or more components is defined and that the components are assigned a unique identification (p. 2243, col. 1, sect 4). Gianaroli et al. shows that unique identification mark is used to verify the components belong to the correct patients (2243, col. 1, sect. 4). Gianaroli et al. shows an embodiment the components that are marked are consists of holders, physician, embryos, oocytes, and spermatozoa (p. 2243, col. 1 -2244, col. 1). Gianaroli et al. shows in an embodiment, that the identification mark assigned to components is different (p. 2244, col. 1, sect. 7.2). Gianaroli et al. shows in an embodiment that the matched set is an embryo and a recipient (p. 2245, col. 1-2). Gianaroli et al. shows in an

Art Unit: 1631

embodiment that the matching set includes a sperm and an oocyte (p. 2243, col. 1, sect. 4). Gianaroli et al. shows an embodiment in which an entity is within a holder and the holder is labeled, reading on the embodiments of at least an entity is within a holder, where the holder is labeled with identification mark and a matching set corresponding to a biological entity and a holder (p. 2245, col.2, sect. 12.6). Gianaroli et al. shows that the identification marks assigned to the components are the same (2243, col. 1, sect. 4). Gianaroli et al. shows an embodiment in which the patient and their records are matched through the assignment of an identification mark (p. 2241, col. 2 sect 2).

Gianaroli et al. does not show that the unique identification is machine-readable.

Whisler et al. shows use of machine-readable identification marks and shows the identification marks are used to control the automatic processing of medical specimens. Whisler et al. shows that the machine-readable identification mark is a barcode (p. 1588, col. 1). Whisler et al. shows that bar-coding is highly accurate and machine-readable information is more reliable than manually entered data (p. 1588, col. 2). Whisler et al. shows that the barcode is readable by scanning (p. 1588, col. 2). Whisler et al. shows the identification mark is an image readable mark (p. 1588, figure 1). Whisler et al. shows that a label having the barcode is affixed to a specimen tube label (p. 1588, col. 2).

It would have been obvious to one of ordinary skill in the art at the time the invention was made to modify procedures of processing IVF components of Gianaroli et al. with the use of barcodes in medical specimen processing of

Art Unit: 1631

Whisler et al. because Whisler et al. shows that bar-coding is highly accurate and machine-readable information is more reliable than manually entered data.

Response to Arguments

Applicant's arguments filed 15 May 2008 have been fully considered but they are not persuasive.

In response to applicant's arguments against the references individually, one cannot show nonobviousness by attacking references individually where the rejections are based on combinations of references. See *In re Keller*, 642 F.2d 413, 208 USPQ 871 (CCPA 1981); *In re Merck & Co.*, 800 F.2d 1091, 231 USPQ 375 (Fed. Cir. 1986).

The combination of Gianaroli et al. in view of Whisler et al. shows a method of controlling the processing of components for *in vitro* fertilization (IVF) using machine readable identification marks. Gianaroli et al. provides methodology presented by the European Society for Human Reproduction and Embryology (ESHRE) for good practices in *In vitro* fertilization laboratories with in the health industry. The methodology or guidelines set forth by the ESHRE provide techniques, procedures and strategies to ensure the highest quality practices in reproductive medicine. Gianaroli et al. provides motivation to increase compliance with the methodology because non-compliance compromises the health and safety of the workers and patients and may result in the loss of gametes and/or embryos. As indicated in the rejection above the element that Gianaroli et al. do not show is a machine readable identification mark of the specimens for *in vitro* fertilization. However, the application of

Art Unit: 1631

machine readable identification marks in the health industry is described by Whisler et al. Thus as set forth in the rejection above, one of ordinary skill would have modified the procedures of Gianaroli et al. with the machine readable identification marks of Whisler et al. because Whisler et al. shows machine readable information, such as identification marks and barcodes are highly accurate and more reliable than manually entered data. The motivation provided by Whisler et al. is compatible with the goals of the ESHRE methods of ensuring the highest quality practices in reproductive medicine and would result in a decrease of errors due to manual sample tracking which Whisler et al. estimate to occur at a rate of 10^9 higher than machine tracked samples. The rejection is maintained.

Conclusion

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after the end of the **THREE-MONTH** shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than **SIX MONTHS** from the mailing date of this final action.

Art Unit: 1631

Any inquiry concerning this communication or earlier communications from the examiner should be directed to KARLHEINZ R. SKOWRONEK whose telephone number is (571) 272-9047. The examiner can normally be reached on 8:00am-5:00pm Monday-Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Marjorie Moran can be reached on (571) 272-0720. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

12 August 2008

/K. R. S./

Examiner, Art Unit 1631

/John S. Brusca/

Primary Examiner, Art Unit 1631